Fundación Favaloro
Transcription
Fundación Favaloro
Reemplazo Valvular Aórtico por Cateterismo (TAVR) Prevención de Complicaciones Oscar A. Mendiz.MD.FACC.FSCAI Jefe Cardiología Intervencionista Presidente SOLACI Fundación Favaloro Fundación Favaloro Tuesday, December 11, 12 Disclosure Speacker: O Mendiz MD. Proctor Medtronic Fundación Favaloro Tuesday, December 11, 12 § Indicación Adecuada: § § § EAo severa sintomática Alto riesgo Quirúrgico Anatomía favorable § Elegir el momento correcto § Tener el Equipo (Team) § Realizar en Lugar correcto § § § § § THOMAS WALTHER & JÖRG KEMPFERT EJCTS 2011 Cortesía Dr Batellini Tuesday, December 11, 12 EAo sintomática severa Paciente compensado Interdisciplinario Quirófano Híbrido o Cath Lab Adecuado Fundación Favaloro Pa#ent Selec#on 1. Iden'fy the high or prohibi've risk surgical pa'ent 2. Anatomical characteris'cs and boundaries of the cardiovascular system from “skin to heart” a) b) Feasibility Vascular access site Fundación Favaloro Tuesday, December 11, 12 High Risk AVR Patients Radiation chest wall/heart disease Octogenarians with multiple co-morbidities STS Predicted Risk >10%, Logistic EuroSCORE >30% (~10-15% operative risk) Cirrhosis with portal hypertension ESRD on dialysis Porcelain aorta Degenerative neurocognitive dysfunction Fundación Favaloro Tuesday, December 11, 12 High Risk AVR Patients Radiation chest wall/heart disease Octogenarians with multiple co-morbidities STS Predicted Risk >10%, Logistic EuroSCORE >30% (~10-15% operative risk) Cirrhosis with portal hypertension ESRD on dialysis Porcelain aorta Degenerative neurocognitive dysfunction There is no perfect formula! Requires some quantitative risk algorithm + a thoughtful surgeon/cardiologist!!! Fundación Favaloro Tuesday, December 11, 12 Percutaneous Aortic Valve Replacement CoreValve Edwards-SAPIEN Fundación Favaloro Tuesday, December 11, 12 Percutaneous Aortic Valve Replacement CoreValve Edwards-SAPIEN Fundación Favaloro Tuesday, December 11, 12 Algorithm for Patient Selection @ Favaloro Foundation First: l Transthoracic Echo for Diagnosis Second: l Catheterization l l l Coronary Angiography (CAD should be previously treated) Thoracic Aortogram (marked pigtail) Abdominal Aortogram (marked pigtail) Third: CT Multislice (thoracic and abdominal aorta) • Finally: TEE: Focus in all needed measurements (advised operator) Fundación Favaloro Tuesday, December 11, 12 Screening: Angiographic Evaluation Fundación Favaloro Tuesday, December 11, 12 TAVR @ Favaloro Foundation Fundación Favaloro Tuesday, December 11, 12 TAVI @ Favaloro Foundation Pte Selection: Don’t forget CT axial slices Good Candidate for Femoral Approach Poor Candidate for Femoral Approach Fundación Favaloro Tuesday, December 11, 12 Screening Mistakes: Annulus Discrepancies Improving with learning curve. Use 3 methods. Fundación Favaloro Tuesday, December 11, 12 TAVR: Better Pte. & Valve Selection Fundación Favaloro Tuesday, December 11, 12 A Limitation of Echo ? It is possible a true diameter is not measured due to the imaging plane acquired 1. Piazza N, et al. Circ Cardiovasc Intervent. 2008;1(1):74-81. Tuesday, December 11, 12 Fundación Favaloro A Limitation of Echo ? It is possible a true diameter is not measured due to the imaging plane acquired 1. Piazza N, et al. Circ Cardiovasc Intervent. 2008;1(1):74-81. Tuesday, December 11, 12 Fundación Favaloro The Aortic Annulus The aor'c annulus is typically non-‐circular Double-oblique axial images at the aortic annular plane Courtesy of Dr. Piazza and Prof. Lange, German Heart Center, Munich Germany Fundación Favaloro Tuesday, December 11, 12 Clinician Publications: Imaging Courtesy E Grube Tuesday, December 11, 12 Fundación Favaloro Clinician Publications: Imaging 1. Sizing is an important part of pre-case planning for TAVI 2. Most current literature suggests a multimodality approach and many prefer 3D method (MSCT) Courtesy E Grube Tuesday, December 11, 12 Fundación Favaloro Hayashida K, et al. EuroInterven#on 2012;8:546-‐555 Fundación Favaloro Tuesday, December 11, 12 Hayashida K, et al. EuroInterven#on 2012;8:546-‐555 Fundación Favaloro Tuesday, December 11, 12 Diameter Range (mm) Perimeter Range (mm) Area Range (mm2) 18 - 20 56.5 - 62.8 254.5 - 314.2 20 - 23 62.8 - 72.3 314.2 - 415.5 23 - 27 72.3 - 84.8 415.5 - 572.6 26 - 29 81.7 - 91.1 530.9 – 660.5 Hayashida K, et al. EuroInterven#on 2012;8:546-‐555 Fundación Favaloro Tuesday, December 11, 12 Messika-Zeitoun D et al. J Am Coll Cardiol 2010;55(3)186-194 Tuesday, December 11, 12 Fundación Favaloro Messika-Zeitoun D et al. J Am Coll Cardiol 2010;55(3)186-194 Tuesday, December 11, 12 Fundación Favaloro Messika-Zeitoun D et al. J Am Coll Cardiol 2010;55(3)186-194 Tuesday, December 11, 12 Fundación Favaloro Multimodal Assessment of Aortic Annulus Correlation TE & ETE TTE & MSCT Messika-Zeitoun D et al. J Am Coll Cardiol 2010;55(3)186-194 Tuesday, December 11, 12 ETE & MSCT Fundación Favaloro Multimodal Assessment of Aortic Annulus Correlation TE & ETE TTE & MSCT ETE & MSCT TAVI Strategy would have been different in 17% Messika-Zeitoun D et al. J Am Coll Cardiol 2010;55(3)186-194 Tuesday, December 11, 12 Fundación Favaloro Multimodal Assessment of Aortic Annulus Correlation TE & ETE TAVI Strategy would have been different in 17% TTE & MSCT TAVI Strategy would have been different in 40% & 42% Messika-Zeitoun D et al. J Am Coll Cardiol 2010;55(3)186-194 Tuesday, December 11, 12 ETE & MSCT Fundación Favaloro Fundación Favaloro Tuesday, December 11, 12 Tamburini C. TCT 2012 Tuesday, December 11, 12 Fundación Favaloro Tamburini C. TCT 2012 Tuesday, December 11, 12 Fundación Favaloro CoreValve Sizing Prosthesis Annulus Perimeter %oversizing Fundación Favaloro Tuesday, December 11, 12 TAVR: Avoiding Perforations Fundación Favaloro Tuesday, December 11, 12 Avoid Perforations Pacemaker: l With distal balloon tip Left Ventricule: l l l Crossing the Valve (“J” or soft wires) Soft entrance of the catheter (push & pulling) Curve shape of stiff wire (small loop) Check by Echo before leaving the Cath Lab Fundación Favaloro Tuesday, December 11, 12 TAVRI: Avoid Perforations Pacemaker with distal balloon Fundación Favaloro Tuesday, December 11, 12 TAVRI: Avoid Perforations Pacemaker with distal balloon Fundación Favaloro Tuesday, December 11, 12 Perforation: Urgent Perdicardial Dranaige CASO 3 Fundación Favaloro Tuesday, December 11, 12 TAVR: Correct Positioning Fundación Favaloro Tuesday, December 11, 12 Valve Positioning Aortic Root perpendicular alignment: l Angio: RAO caudal (10/20) or LAO cranial (10/10) l Paeion system Dyna CT system. l Delivery Alignment: Fundación Favaloro Tuesday, December 11, 12 Dyna CT System Fundación Favaloro Tuesday, December 11, 12 Correct positioning Fundación Favaloro Tuesday, December 11, 12 Buscar la adecuada alineación de los senos Aortograma en oblicua derecha y luego en derecha caudal con mejor alineación Fundación Favaloro Tuesday, December 11, 12 Buscar la adecuada alineación de los senos Aortograma en oblicua derecha y luego en derecha caudal con mejor alineación Fundación Favaloro Tuesday, December 11, 12 Starting Valve Delivery CASO 3 Ring postioning Try to see 3 cusped Fundación Favaloro Tuesday, December 11, 12 Design of the CoreValve Prosthesis Photograph provided by Piazza, Serruys, and DeJaegere Photograph provided by Piazza, Serruys, and DeJaegere Photograph provided by Piazza, Serruys, and DeJaegere Skirt height ~ 12 mm Fundación Favaloro Tuesday, December 11, 12 Starting Valve Delivery 4mm 7-8mm Good Starting Too Deep!!! Fundación Favaloro Tuesday, December 11, 12 Valve-in-Valve TAVR: Fundación Favaloro Fundación Favaloro Tuesday, December 11, 12 Valve-in-Valve TAVR: Fundación Favaloro Fundación Favaloro Tuesday, December 11, 12 Valve-in-Valve TAVR: Fundación Favaloro Fundación Favaloro Tuesday, December 11, 12 Strategies to Manage Device Malposi#on Prosthesis too high Retrieve while still attached l Implantation of a second valve l Valve in valve l Prosthesis too low Pull while still attached l Snare and pull l Valve in valve l Fundación Favaloro Tuesday, December 11, 12 Device Malposi#on: Prosthesis Too High Fundación Favaloro Tuesday, December 11, 12 Device Malposi#on: Prosthesis Too High Fundación Favaloro Tuesday, December 11, 12 Device Malposi#on: Prosthesis Too High Fundación Favaloro Tuesday, December 11, 12 Prosthesis Too High: Retrieval Prosthesis Retrieval Prosthesis Retrieved into Abd Aorta Fundación Favaloro Tuesday, December 11, 12 Prosthesis Too High: Retrieval Prosthesis Retrieval Prosthesis Retrieved into Abd Aorta Fundación Favaloro Tuesday, December 11, 12 Prosthesis Too High: Retrieval Prosthesis Retrieval Prosthesis Retrieved into Abd Aorta Fundación Favaloro Tuesday, December 11, 12 Prosthesis Too High: Retrieval Prosthesis Retrieval into Sheath Prosthesis Removed via Sheath Fundación Favaloro Tuesday, December 11, 12 Prosthesis Too High: Retrieval Prosthesis Retrieval into Sheath Prosthesis Removed via Sheath Fundación Favaloro Tuesday, December 11, 12 Prosthesis Retrieval Risk of stroke with prosthesis retrieval Fundación Favaloro Tuesday, December 11, 12 Desplazamiento a la aorta ascendente e implante de 2° válvula Aortograma con válvula desplazada a la Ao ascedente por lo que se la retiró con lazo Fundación Favaloro Tuesday, December 11, 12 Desplazamiento a la aorta ascendente e implante de 2° válvula Mismo paciente con implante de una 2° válvula y aortograma final Fundación Favaloro Tuesday, December 11, 12 Fundación Favaloro Tuesday, December 11, 12 Valve Too Deep: Pulling Maneuver CASO 3 Fundación Favaloro Tuesday, December 11, 12 Valve Too Deep: Pulling Maneuver CASO 3 Aortic Arch rectification Fundación Favaloro Tuesday, December 11, 12 CASE 6: Angulated aorta: Valve Too Deep Fundación Favaloro Tuesday, December 11, 12 CASE 6: Angulated aorta: Valve Too Deep Fundación Favaloro Tuesday, December 11, 12 Valve Hoocks Full Detachment !!!! CASO 3 Fundación Favaloro Tuesday, December 11, 12 Valve Hoocks Full Detachment !!!! CASO 3 Fundación Favaloro Tuesday, December 11, 12 Valve Hoocks Full Detachment !!!! CASO 3 Be carefull Fundación Favaloro Tuesday, December 11, 12 Valve Hoocks Full Detachment !!!! CASO 3 Fundación Favaloro Tuesday, December 11, 12 Valve Hoocks Full Detachment !!!! CASO 3 Fundación Favaloro Tuesday, December 11, 12 Valve Hoocks Full Detachment !!!! CASO 3 Fundación Favaloro Tuesday, December 11, 12 Delivery trabado en el Ca Posicionamiento de la válvula e imposibilidad de retirar el delivery por el Ca Fundación Favaloro Tuesday, December 11, 12 Delivery trabado en el Ca Post dilatación con delivery y aortograma final Fundación Favaloro Tuesday, December 11, 12 Valve Positioning & Delivery: Hemodynamic Stability Fundación Favaloro Tuesday, December 11, 12 Evitar la hipotensión durante la liberación especialmente en pacientes con baja FEVI VI diátole VI sístole Fundación Favaloro Tuesday, December 11, 12 TAVR: Vascular Access Complications Fundación Favaloro Tuesday, December 11, 12 Vascular Complications Bleeding Vessel obstruction (Vessel rupture) Grube ISET Miami 2012 Tuesday, December 11, 12 Fundación Favaloro Early Vascular Access Complications Relationship to 1 Year Mortality (NB 22/24F Device) 59 Approach % Survival in Pts who did not have vascular access complications % Survival in Pts who did have vascular access complications P-Value TF 83.9% 72.2% 0.0121 TA 73.2% 47.4% 0.0188 Ganesh Manoharan Tuesday, December 11, 12 Fundación Favaloro Early Vascular Access Complications Relationship to 1 Year Mortality (NB 22/24F Device) 59 Approach % Survival in Pts who did not have vascular access complications % Survival in Pts who did have vascular access complications P-Value TF 83.9% 72.2% 0.0121 TA 73.2% 47.4% 0.0188 Ganesh Manoharan Tuesday, December 11, 12 Fundación Favaloro Percutaneous TAVI Fundación Favaloro Tuesday, December 11, 12 Correct puncture site Fundación Favaloro Tuesday, December 11, 12 Correct puncture site Fundación Favaloro Tuesday, December 11, 12 Vascular Access Mistakes Prostar 10XL after 9 F predilatation Site access predilatation (smaller sheath) Prostar delivery under fluoro. Contralateral access for bleeding control. Stent graft back-up. Surgcial back up Fundación Favaloro Tuesday, December 11, 12 Vascular Access Mistakes Prostar 10XL after 9 F predilatation Site access predilatation (smaller sheath) Prostar delivery under fluoro. Contralateral access for bleeding control. Stent graft back-up. Surgcial back up Fundación Favaloro Tuesday, December 11, 12 Prevención complicaciones vasculares, infección herida quirúrgica y linfocele Cierre percutáneo con Prostar XL y angiografía de control Fundación Favaloro Tuesday, December 11, 12 Estenosis por cierre percutáneo Estenosis por cierre percutáneo Angioplastia con balón Angiografía final Fundación Favaloro Tuesday, December 11, 12 InSeal Intravascular Closure Device Acute Tether (biodegradable) Sealing membrane (biodegradable) Grube ISET Miami 2012 Tuesday, December 11, 12 After biodegradation Nitinol frame Fundación Favaloro TAVR: Stroke Fundación Favaloro Tuesday, December 11, 12 Cerebral Embolism after TAVI 73% of TAVI patients had new cerebral lesions after TAVI A DW-MRI in a 73-year-old man demonstrates multiple, bilateral embolism of the cerebrum and cerebellum (white arrows). Selected emboli demonstrate signal intensity in the fluidattenuated inversion recovery sequence as sign of neuronal repair (yellow arrows). The patient had no clinically apparent focal neurological deficits after TAVI (NIHSS: 0). Fundación Favaloro JACC 2010 Tuesday, December 11, 12 Addressing Stroke Risk Poten&al Issues Embolic material released during the procedure Post-‐implant events Solu&ons • Alterna've access routes • Embolic protec'on devices • An'-‐coagula'on management— guidelines and training • Differen'a'ng late-‐diagnosis Fundación Favaloro Tuesday, December 11, 12 Cerebral Embolic Protection Device Embrella Embolic Deflector Device Claret Dual Filter Device Fundación Favaloro Tuesday, December 11, 12 Improving Technique: TAVI Direct (n=63) Fundación Favaloro Tuesday, December 11, 12 Timing, Predictive factors and Prognostic value of cerebrovascular events in a large cohort of patients undergoing TAVI Prospective Registry, 5 hotspital, 1081 Ptes (Edwards & CoreValve) Incidence: -Acute: 5.1% (0.8 transient) -1-year 3.1% Predictors: -Acute Phase: Post dilatation; Valve Deformation/detachment -Follow-Up: atrial fibrialtion CVE 2.7 2.7 3.0 2.6 2.5 CVE 2.3 2.4 1.5 2.3 0.8 2.2 0 Acute (<24hs) Sub-acute (1-30 days) Nombela-Franco L, et al. TCT 12 abstract Nro 89. Quebec Heart & Lung Institute www.solaci.org Tuesday, December 11, 12 2.8 1.4 Major Minor Fundación Favaloro TAVR: Paravalvular Leak & AI Fundación Favaloro Tuesday, December 11, 12 Mechanisms of peri-prosthetic AR Shallow implantation Deep implantation Prosthesis-annulus size mismatch Sinning JM et al., JACC 2012 Tuesday, December 11, 12 Fundación Favaloro Paravalvular AR and Mortality TAVR Patients (AT) None - Trace Mortality Mild - Moderate - Severe Months Post Procedure Numbers at Risk None-Tr 167 149 140 126 87 41 16 Mild-Mod-Sev 160 134 112 101 64 26 12 Fundación Favaloro Tuesday, December 11, 12 Paravalvular AR and Mortality TAVR Patients (AT) None - Trace Mortality Mild - Moderate - Severe 24.8% 14.5% Months Post Procedure Numbers at Risk None-Tr 167 149 140 126 87 41 16 Mild-Mod-Sev 160 134 112 101 64 26 12 Fundación Favaloro Tuesday, December 11, 12 Paravalvular AR and Mortality TAVR Patients (AT) HR [95% CI] = 2.01 [1.38, 2.92] p (log rank) = 0.0002 None - Trace Mild - Moderate - Severe Mortality 39.5% 29.5% 24.8% 14.5% Months Post Procedure Numbers at Risk None-Tr 167 149 140 126 87 41 16 Mild-Mod-Sev 160 134 112 101 64 26 12 Fundación Favaloro Tuesday, December 11, 12 Mild Paravalvular AR and Mortality TAVR Patients (AT) None - Trace Mild Mortality Moderate - Severe 24.8% 14.5% Months Post Procedure Numbers at Risk None-Tr 167 149 140 126 87 41 16 Mild 136 115 95 86 51 21 10 24 19 17 15 13 5 2 Mod-Sev Tuesday, December 11, 12 Fundación Favaloro Mild Paravalvular AR and Mortality TAVR Patients (AT) None - Trace Mild Mortality Moderate - Severe 39.2% 29.5% 24.8% 14.5% Months Post Procedure Numbers at Risk None-Tr 167 149 140 126 87 41 16 Mild 136 115 95 86 51 21 10 24 19 17 15 13 5 2 Mod-Sev Tuesday, December 11, 12 Fundación Favaloro Mild Paravalvular AR and Mortality TAVR Patients (AT) p (log rank) < 0.001 None - Trace Mild Moderate - Severe Mortality 41.7% 39.2% 29.5% 29.2% 24.8% 14.5% Months Post Procedure Numbers at Risk None-Tr 167 149 140 126 87 41 16 Mild 136 115 95 86 51 21 10 24 19 17 15 13 5 2 Mod-Sev Tuesday, December 11, 12 Fundación Favaloro METHODS: • Dimensionless AR index [(DBP-LVEDP)/SBP] X 100 used to determine the significance of PVL in 146 TAVR pts RESULTS: • AR index <25 predicts ↑ 1-yr mortality (46.0% vs. 16.7%, p<0.001); ind pred of 1-yr mortality beyond TEE measures of PVL severity Sinning et al. J Am Coll Cardiol 2012; 59: 1134-41 Tuesday, December 11, 12 Fundación Favaloro Aortic Regurgitation Index: Mild AR Fundación Favaloro Tuesday, December 11, 12 Aortic Regurgitation Index: Mild AR Fundación Favaloro Tuesday, December 11, 12 Aortic Regurgitation Index: Mild AR Fundación Favaloro Tuesday, December 11, 12 Aortic Regurgitation Index: Mild AR RRsys 150 mmHg RRdia 60 mmHg LVEDP 15 mmHg Fundación Favaloro Tuesday, December 11, 12 Aortic Regurgitation Index: Mild AR RRsys 150 mmHg RRdia 60 mmHg LVEDP 15 mmHg Aor'c regurgita'on Index = [(RRdia – LVEDP) / RRsys] x 100 Tuesday, December 11, 12 = [(60 -‐ 15) / 150] x 100 = 30.0 Fundación Favaloro Aortic Regurgitation Index: Moderate AR Fundación Favaloro Tuesday, December 11, 12 Aortic Regurgitation Index: Moderate AR Fundación Favaloro Tuesday, December 11, 12 Aortic Regurgitation Index: Moderate AR Fundación Favaloro Tuesday, December 11, 12 Aortic Regurgitation Index: Moderate AR RRsys 120 mmHg RRdia 40 mmHg LVEDP 20 mmHg Fundación Favaloro Tuesday, December 11, 12 Aortic Regurgitation Index: Moderate AR RRsys 120 mmHg RRdia 40 mmHg LVEDP 20 mmHg Aor'c regurgita'on Index = [(RRdia – LVEDP) / RRsys] x 100 Tuesday, December 11, 12 = [(40 – 20) / 120] x 100 = 16.7 Fundación Favaloro Mecanismos Involucrados en la Aparición de Leak PROTESIS Tamaños -Medición Anillo -Relación Ani/Val Posición -Técnica -Alineación -Profundida Adaptada de Tamburino C. TCT2012 Tuesday, December 11, 12 Expanción -Circularidad -Calcio -Stent frame -Fuerza Radial Aposición -Calcio -Bi/Tricúspide Fundación Favaloro Strategies to Manage Paravalvular Leak Hemodynamic assessment Under-deployed valve l Post-dilate Problem of valve positioning l Snare and pull l Valve in valve Fundación Favaloro Tuesday, December 11, 12 TAVR: Clinical Outcomes Fundación Favaloro Tuesday, December 11, 12 Outcomes after TAVR using VARC criteria: Review of the literature and a study-level meta-analysis of 3,519 patients from 17 studies Philippe Généreux, MD Stuart Head Columbia University Med Center Cardiovascular Research Center New York City Erasmus University Med Center Rotterdam, the Netherlands VARC – 2 Meeting Washington DC; September 26, 2011 Fundación Favaloro Tuesday, December 11, 12 TAVR Outcomes - VARC Meta-Analysis (17 studies; 3,519 patients) J Am Coll Cardiol 2012;59:2297-306 Fundación Favaloro Tuesday, December 11, 12 TAVR Outcomes - VARC Meta-Analysis (17 studies; 3,519 patients) P Généreux and S.J.Head Unpublished data/Submitted JACC Tuesday, December 11, 12 Fundación Favaloro Predictive Factors of 30-day Mortality Pulmonary Hypertension OR: 2.09, 95% CI: 1.02-4.43, P=0.048 Severe Mitral Regurgitation OR: 3.01, 95% CI: 1.09-8.24, P=0.033 Need for peri-procedural hemodynamic support Josep Rodés-Cabau, Canadian Registry, ACC 12, Tuesday, December 11, 12 OR: 6.84, 95% CI: 2.04-22.93, P=0.002 Fundación Favaloro Procedural Predictors of Mortality Stroke HR [95% CI] p-value TAVR 2.76 [1.58-4.82] <0.001 AVR 4.99 [2.85-8.75] <0.001 TAVR 2.14 [1.42-3.20] <0.001 AVR 2.88 [1.99-4.14] <0.001 TAVR 1.67 [1.04-2.70] 0.03 AVR 1.40 [0.57-3.44] 0.46 Major Bleeding Major Vascular Fundación Favaloro Tuesday, December 11, 12 Transcatheter Aortic Valve Replacement: Outcomes of Pts with Moderate or Severe Mitral Regurgitation 451 pts stratified by MR status (71% mild, 29% moderate/severe). Moderate/Severe vs. Mild MR Adjusted HR for Mortality 95% CI P Value ≤ 30 Days 2.10 1.12-3.94 0.02 > 30 Days 0.82 0.50-1.34 0.42 At 1 year, MR was improved in 55% of patients with moderate or severe MR at baseline. Conclusion: Moderate/severe MR in pts undergoing TAVR is associated with higher early— but not late—mortality, with improvements in MR in over half of survivors at 1 year. Toggweiler S, et al. J Am Coll Cardiol. 2012;Epub ahead of print. Fundación Favaloro Tuesday, December 11, 12 Left Bundle Branch Block (LBBB) Induced by TAVI Increases Risk of Death Registry study of 679 pts receiving either CoreValve or Sapien at 8 Dutch centers. About one-third (n = 233) of pts experienced new LBBB within 7 days of implantation At 450-day follow-up, all-cause mortality higher in patients with LBBB vs. without (37.8% vs. 24.0%; P = 0.002) New LBBB more common in CoreValve- vs. Sapien-treated patients (51.1% vs. 12.0%; P < 0.001) Implications: LBBB is a serious complication of TAVR that may strongly attenuate the survival benefit of this procedure. Houthuizen P, et al. Circulation. 2012;Epub ahead of print. Tuesday, December 11, 12 Fundación Favaloro TAVR in Pts with Severe Left Ventricular Dysfunction Retrospective analysis of 2-center experience that stratified patients according to baseline LVEF. LVEF ≤ 35% LVEF > 35% (n = 50) (n = 334) Periprosthetic Leak > 2+/4 10% 3% 0.027 30-Day Mortality 10% 3% 0.010 Outcomes After TAVR P Value In pts with severe LV dysfunction, LVEF increased from 27.7 ± 6.0% at baseline to 35.4 ± 11.1% at discharge (P < 0.0001). Conclusion: TAVR offers immediate and lasting benefit to patients with severe left ventricular dysfunction at an acceptable mortality risk. Fraccaro C, et al. Circ Cardiovasc Interv. 2012;Epub ahead of print. Fundación Favaloro Tuesday, December 11, 12 TAVR: Permanent Pacemaker Fundación Favaloro Tuesday, December 11, 12 Meta-Analysis – PPM 50.0 42.5 40 95% CI: 20.6-36.8% 35.2 37.5 28.7 23 25.0 28.7% 25.7 26 16.6 12.5 Italian Belgian French Spanish UK German Auz-NZ Meta-Analysis3 0 PPM Tuesday, December 11, 12 Fundación Favaloro Depth of Implantation May Play a Role in Onset of Rhythm Disturbances1 New-onset LBBB acquired during or after valve implantation 10.3 mm No new-onset LBBB or new-onset LBBB acquired during procedure but before valve implantation 7.3 mm 6.0 mm below coronary sinus 1Grube, et al. TCT Asia 2010 Tuesday, December 11, 12 Fundación Favaloro Primary TAVI: Clinical Outcome at 30days Study Group Control Group n=60 n=126 6.7% (4) 14.3% (18) 0 5.6% (7) 5.0% (3) 11.9% (15) 11.7% (7) 27.8% (35) 10.0% (6) 9.5% (12) All-cause Mortality Myocardial infarction Stroke/TIA Need for pacemaker implantation Vascular Access Complication *Buellesfeld L et al. J Am Coll Cardiol. 2011; 57:1650-1657 Tuesday, December 11, 12 Fundación Favaloro TCT12 Abstract 90: Predictive Factors and long-term clinical consequences of persistent LBBB following aortic valve implantation with balloon expandable valve Nuevo BCRI 30% Predictores lProfundidad 37% lDuración 24% QRS previo Consecuencias: lNO AUMENTO MORTALIDAD lPredijo pero capacidad funcional y función ventricular. Urena L, TCT12, abstract 90 Tuesday, December 11, 12 Fundación Favaloro Experiencia en Fund Favaloro: Resultados a 30 días Variable n° 72 pacientes Edad (años) Masculino (%) 80±8 42 (58) Antecedente de IAM (%) Antecedente CRM (%) Antecedente ATC (%) 14 (19) 13 (18) 27 (38) Antecedente IRC (%) Antecedente EPOC Severo (%) 8 (11) 12 (17) Fracción de eyección menor a 40% Euroscore logístico Insuficiencia mitral 3-4 (%) 8 (11) 21.4±0.15 13 (18) Fundación Favaloro Tuesday, December 11, 12 Experiencia en Fund Favaloro: Resultados a 30 días Eventos adversos a 30 días Éxito procedimiento n° patients (%) 70 (97) Muerte (%) 2 (3) Perforación cardíaca con pericardiocentesis (%) 3 (4) Insuficiencia cardíaca (%) A.C.V. Menor (%) Marcapaso definitivo (%) Insuficiencia renal aguda (%) B.C.R.I. Definitivo (%) 20 (28) 1 (2) 20 (28) 2 (3) 17 (24) Fundación Favaloro Tuesday, December 11, 12 Experiencia en Fund Favaloro: Follow-Up Evolución alejada n° 70 patients (86%) 12±11 Período de seguimiento (2-35 meses) Muerte de cualquier causa (%) 6 (8.6) IAM (%) 1 (1.4) ACV Menor + TIA (%) 2 (2.8) Marcapaso definitivo (%) 2 (2.8) Asintomáticos (%) Mediciones Aortic valve area (cm²) Gradiente pico Hemodinamia / Eco-Doppler (mmHg) Insuficiencia aórtica leve final (%) Insuficiencia aórtica moderada final (%) 62 (85.7) Pre Implante Valvular 0.6±0.2 89±10 / 91±12 Post implante Valvular 1.7±0.2 3±1 / 13±10 36 (50) 32 (44) Fundación Favaloro Tuesday, December 11, 12 Fundación Favaloro Fundación Favaloro Tuesday, December 11, 12 Gracias por su Atención Fundación Favaloro Fundación Favaloro Tuesday, December 11, 12 Fundación Favaloro Tuesday, December 11, 12 Subclavian Access Fundación Favaloro Fundación Favaloro Tuesday, December 11, 12 Fundación Favaloro Tuesday, December 11, 12